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Purpose.T oe v a l u a t et h es a f e t ya n de ﬃcacy of the Possis rheolytic thrombectomy with or without indwelling catheter-directed
pharmacolysis for the treatment of massive pulmonary embolus in patients presenting with right heart strain and/or a pulseless
electrical activity (PEA). Materials and Methods. Retrospective review of patients undergoing pulmonary pharmacolysis was
performed (07/2004–06/2009). Pre- and posttreatment Miller index scoring weres calculated and compared. Patients were
evaluated for tPA doses, ICU stay, hospital stay, and survival by Kaplan-Meier analysis. Results. 11 patients with massive PE were
found, with 10/11 presenting with a Miller score of >17 (range: 16–27, mean: 23.2). CTPA and/or echocardiographic evidence
of right heart strain was found in 10/11 patients. 3 (27%) patients presented with a PEA event. Two (18%) patients had a
contraindication to pharmacolysis and were treated with mechanical thrombectomy alone. The intraprocedural mortality was
9% (n = 1/11). Of the 10 patients who survived the initial treatment, 7 patients underwent standard mechanical thrombectomy
initially, while 5 received power pulse spray mechanical thrombectomy. Eight of these 10 patients underwent adjunctive indwelling
catheter-directed thrombolysis. The mean catheter-directed infusion duration was 18 hours (range of 12–26 hours). The average
intraprocedural, infusion, and total doses of tPA were 7mg, 19.7mg, and 26.7mg, respectively. There was a 91% (10/11) technical
success rate. The failure was the single mortality. Average reduction in Miller score was 9.5 or 41% (P = 0.009), obstructive index
of 6.4 or 47% (P = 0.03), and perfusion index of 2.7 or 28% (P = 0.05). Average ICU and hospital stay were 7.4 days (range 2–27
days) and 21.3 days (range 6–60 days), respectively. Intent to treat survival was 90% at 6, 12, and 18 months. Conclusion. Rheolytic
thrombectomy with or without adjunctive catheter-directed thrombolysis provides a safe and eﬀective method for treatment of
acute PE in patients who present with right heart strain and/or a PEA event.
1.Introduction
Pulmonary embolism (PE) is a common event resulting in
an estimated 150,000 deaths per year in the United States,
with an apparent increasing frequency as the sensitivity
of diagnostic imaging improves [1–3]. While the majority
of these patients may be minimally symptomatic and can
be treated medically with anticoagulation alone, patients
with underlying cardiopulmonary disease and those patients
who show right ventricular compromise or hemodynamic
instability may require acute intervention to decrease clot
burden [1, 2, 4]. In patients who present with compromised
hemodynamics or cardiac function, a variety of treatment
options have been utilized to treat acute PE, including
surgical embolectomy, intravenous ﬁbrinolysis, catheter-
directed pharmacolysis, and transcatheter mechanical clot
fragmentation with or without thrombectomy [2, 5–20].
The general aim of catheter-directed therapy in the set-
ting of hemodynamically compromised patients with acute
PE is to debulk and/or redistribute the obstructive clot,2 Thrombosis
rendering it less hemodynamically signiﬁcant [4]. Most
often, mechanical thrombectomy is used alone, and adjunc-
tive use of indwelling transcatheter-directed thrombolytic
infusions is rarely reported [2]. Numerous catheter-directed
mechanical thrombectomy devices have been utilized for
acute PE, including the AngioJet device (Xpeedior Possis
Medical, Minneapolis, Minn) [2, 4–10]. The utilization of
the AngioJet device in the setting of acute PE has been a
controversial topic [2, 4–10]. Prior studies have shown that
the AngioJet can be highly eﬀective in reducing clot burden
[2], however adverse events such as signiﬁcant bradycardia
and even asystole have been reported [1, 4–10].
The purpose of this study is to evaluate the safety,
eﬀectiveness, and long-term outcome of rheolytic thrombec-
tomy using the Angiojet Possis device with or without
the supplemental use of catheter-directed thrombolysis in
patients with acute pulmonary emboli who present with
right heart strain and/or pulseless electrical activity.
2.MaterialsandMethods
2.1. Patient Population. A retrospective analysis was per-
formed of all consecutive patients treated for acute pul-
monary embolus (PE) by endovascular means from July
2004 to June 2009. Internal Review Board permission for
the study was obtained based upon the secondary use
of anonymous data. Patients with tumor embolus were
excluded from the study. Catheter-directed techniques for
management of acute PE were utilized in patients in whom
there was a large clot burden and evidence of hemodynamic
instability and/or right heart strain. Patients were noted for
their age and gender. Pulmonary embolism was diagnosed
by a contrast-enhanced computed tomography pulmonary
arteriogram (CTPA). Echocardiography was also performed
in several patients at the discretion of the referring physician
to evaluate right heart function.
2.2. Deﬁnitions. Massive PE was classiﬁed by CTPA criteria
as having a Miller score of >17 and/or CTPA and/or
echocardiographic evidence of right heart strain [21]. The
Miller score is a sum of two components: (1) obstructive
index and (2) perfusion index [21]. Right ventricular heart
strain by CTPA was deﬁned as paradoxical bowing of the
interventricular septum into the left ventricle during systole
and right ventricular dilatation, with or without dilatation of
the inferior vena cava, the hepatic veins, the coronary sinus,
and the azygous vein [22]. Criteria for right heart strain
on echocardiography include increased right ventricular
size, paradoxical interventricular septal contraction during
systole, and increased pulmonary artery pressures [22, 23].
2.3. Technique. The desired endpoint of catheter-directed
therapy was to debulk (remove or dissolve) thrombus or
redistribute the hemodynamically signiﬁcant clot from the
central pulmonary arteries to the more peripheral branches
to relieve the afterload (strain) on the right ventricle [4].
The intention for all patients was to undergo catheter-
directed mechanical thrombectomy debulking (with or
without intraprocedural pharmacolysis). When there was
no contraindication to thrombolysis, mechanical thrombec-
tomy was followed by at least 12 hours of indwelling
catheter-directed pharmacolysis and a subsequent “second
look” pulmonary angiogram. If there was a contraindication
to pharmacolysis or if signs of bleeding developed during
intraproceduraladministrationofabolusoftissueplasmino-
gen activator (tPA, Alteplase, Genetech, South San Francisco,
Calif), the patients underwent mechanical thrombectomy
without adjunctive indwelling catheter-directed pharmacol-
ysis.
Pulmonary angiograms were performed using standard
angiographic techniques via a transfemoral approach unless
there was chronic inferior vena cava thrombus. In these
instances, a basilic vein approach was chosen for catheter
access. The catheter utilized to catheterize the pulmonary
artery was a 7-French angled pigtail catheter (Monteﬁori, -
Cook, Inc, Bloomington, Ind). Mechanical thrombectomy
was performed utilizing the over-the-wire Possis Angiojet.
The Angiojet has a traditional suction rheolytic mode, but
it can be used in a power pulse-spray mode [24]. Either
the standard, power pulse spray, or both methods were
used during mechanical thrombectomy, depending on the
operator’s discretion.
The traditional suction rheolytic mode of the AngioJet
relies on retrograde injection of high-pressure saline jets
to create a low-pressure zone around the openings near
the catheter tip (Bernoulli principle). The recirculating
heparinized saline creates a vortex (Venturi eﬀect) causing
fragmentation of the thrombus into smaller fragments. The
injectedsalineandfragmentedthrombusareremovedviathe
suction lumen of the device resulting in an euvolemic state
while debulking, removing, and redistribution of the emboli.
The saline used can be mixed with heparin or tPA. The
power pulse-spray mode is when the suction lumen of the
AngioJet device is blocked with a stopcock, which generates
a powerful spray when the device is activated. This spray will
notonlymechanicallyfragmentclot,butalsodelivertPAinto
the interstices of the clot and potentially activate more clot-
bound plasminogen to eﬀect more rapid pharmacolysis of
the clot [24].
When no contraindication to or active bleeding devel-
oped after intraprocedural tPA administration existed, post-
procedural indwelling catheter-directed tPA thrombolysis
with tPA was performed. The catheters utilized for tPA
administration were either 5-French infusion multisidehole
catheters with 10-centimeter infusion lengths or 5-French
diagnostic pigtail catheters. After indwelling transcatheter
pharmacolysis, surviving patients were returned for a com-
pletion pulmonary angiogram and discontinuation of the
infusion catheters.
2.4. Study Endpoints and Followup. Thrombus burden was
calculated for all patients using the obstructive index
(Numberofsegmentalarteriesinvolved-OI),perfusionindex
(Relative blood ﬂow to upper, mid and lower lung zones-
PI), and Miller index score (Summation of OI and PI)
preprocedurally using both CTPA and angiographic images
andrescoredbasedupontheposttreatmentangiograms[21].Thrombosis 3
Table 1: Cardiopulmonary status and Possis Angiojet and technical details.
Patients
Cardioplumonary status Possis Angiojet mode tPA dose and administration route




Patient #1 25 No CTPA + Echo No Yes 4mg 12mg 16mg
Patient #2 17 Yes CTPA + Echo No Yes 8mg 21mg 29mg
Patient #3 21 Yes CTPA Yes Yes 8mg 14mg 22mg
Patient #4 16 Yes CTPA + Echo Yes Yes 6mg 21mg 27mg
Patient #5∗ 26 No CTPA + Echo No Yes No No No
P atient#6 24 No CTP A+Echo Y es No 10mg 14mg 24mg
Patient #7 25 No CTPA Yes Yes 8mg 18mg 26mg
P a t i e n t # 8 2 7 N oE c h oN o Y e s + T N oN o ∗∗ No∗∗
Patient #9 25 No CTPA + Echo Yes No 8mg 26mg 34mg
Patient #10 24 No Echo No Yes 4mg 31.5mg 35.5mg
Patient #11 25 No Echo No Yes + T∗∗∗ Patient Died
∗Patient had glioblastoma multiform (GBM) and was contraindicated to ﬁbrinolysis.
∗∗Patient had active epistaxis and did no undergo postprocedural catheter-directed ﬁbrinolysis.
∗∗∗The intention was to use aspiration Possis rheolytic, however, patient died on the table prior to its use. An Arrow-Trerotola PTD device was used (Arrow
Intl. Inc. Reading, Pa).
+T: Arrow-Trerotola PTD device used (Arrow Intl. Inc. Reading, Pa).
Technicalsuccesswasdeﬁnedasadecreaseinclotburden
as determined on the immediate posttreatment angiogram.
Minor complications included bleeding not requiring blood
transfusion, transient renal dysfunction not requiring the
need for dialysis, and/or catheter induced arrhythmias-not
requiring treatment. Major complications were deﬁned as
bleeding requiring a blood transfusion, intracranial hemor-
rhage, death, arrhythmia requiring treatment, renal failure
requiring hemodialysis, and/or the need for prolonged
hospitalization as a direct result of the treatment [4].
Postprocedure patients were followed, noting the dura-
tion of intensive care unit stay and the number of days of
hospitalization.Afterdischargefromthehospital,thepatient
records were evaluated for clinic visits, complaints, and read-
mission. Full recovery was deﬁned as ambulatory hospital
dischargetohomewithoutcardiopulmonarysequela(i.e.,no
need for home oxygen requirements) or the need for skilled
nursing care.
2.5. Statistical Analysis. The preprocedural and postproce-
dural obstructive index, perfusion index, and Miller score in
allpatientswerecomparedusingStudent’st-testanalysis.AP
value of <0.05 was considered statistically signiﬁcant. Intent




Between 2004 and 2009 (6 years), 12 consecutive patients
with acute PE presented with imaging evidence of right
ventricular strain, hemodynamic instability, or a PEA event
were treated with rheolytic mechanical thrombectomy with
or without adjunctive catheter-directed tPA infusion into
the pulmonary artery clot. One patient was excluded from
analysis for having intraluminal tumor thrombus as the
cause for PE. The mean age of the remaining 11 patients was
60.2 years (range: 15–75 years). Nine patients were male and
2 female. Three patients presented with a PEA event (3/11,
27%). Six of the patients were evaluated with both CTPA and
echocardiography, 3 patients had echocardiography only,
and 2 had CTPA only. Details of the indications of PE
ﬁbrinolysis are in Table 1.
One of the eleven patients had a contraindication to tPA
treatment (intracranial neoplasm) (Patient no.5, Table 1),
and 1 patient died prior to beginning of the intraprocedural
thrombolysis (Patient no.11, Table 1). A third patient exhib-
ited epistaxis during the intraprocedural administration of
tPA and was not treated with indwelling catheter-directed
pharmacolysis after the initial procedure.
Therefore, of the 10 patients treated to completion
(and excluding the one patient who expired), 7 underwent
standard rheolytic thrombectomy, while ﬁve were treated
using the power pulse-spray technique using a tPA mixture
only (the intraprocedure tPA dose ranged from 4–10mg,
mean 7mg) during the initial procedure. The patient who
died in the procedure, died prior to starting rheolytic ther-
apy (mechanical thrombolysis). Eight of these 10 patients
underwent adjunctive postprocedural indwelling catheter-
directed pharmacolysis, Four of these 8 patients had the
infusion administered via a unilateral infusion catheter (3 in
the right pulmonary artery and 1 in the left). Two patients
had bilateral infusion catheters placed, and one patient had
an infusion catheter placed in the right pulmonary artery
and the sheath advanced into the main pulmonary artery for
tPA infusion. The patient with chronic thrombus within the
IVC had an infusion catheter placed in the right pulmonary
artery and another catheter was positioned in the IVC (see4 Thrombosis
(a) (b)
(c) (d)
Figure 1: This is 44-yr-old woman with acute chest pain shortness of breath and tachycardia. Oblique coronal CT image (a) and pulmonary
angiogram (b) showed massive left main and lower lobe PA embolus (arrows). Mean pulmonary artery pressure on initial study was
34mm Hg. A 6-French Angiojet device (arrow) was used (c) followed by catheter-directed thrombolysis for 13 hours. Follow-up angiogram
demonstrated signiﬁcant decrease in clot burden (arrow) (d). Mean pulmonary artery pressure decreased from 34 to 18mmHg.
Figure 1). Technical details of the PE ﬁbrinolysis procedure
including the tPA doses and routes of administration are
shown in Table 1.
The average indwelling transcatheter lysis dose was
19.7mg of tPA, and the average total dose (intraprocedural
and adjunctive infusion of tPA) was 26.7mg tPA. Overnight
infusion of tPA was performed at a total dose of 1.0mg/hr,
with the total dose infused being split between two catheters
if bilateral infusion catheters were placed. Patients returned
for a repeat pulmonary arteriogram the following day.
Infusion time ranged from 12 to 53hrs (average 23.6). Only
one patient required more than 24 hours of lytic infusion,
and this patient presented with acute on chronic PE. Five
of the patients underwent intraprocedure inferior vena cava
(IVC) ﬁlter placement. IVC ﬁlter placement was at operators
discretion.
Technical success on a basis of an intent to treat was
91% (10/11, with the tumor thrombus patient excluded),
with the one failure being the patient that expired during
the procedure. Treatment eﬀects on the Miller score and
its two components are shown in Table 2. These numbers
correlate to a 47% decrease in the degree of obstruction, a
28% decrease in the perfusion index, and 41% decrease in
the overall Miller score (P = 0.009). The eﬀect of treat-
ment on pulmonary artery pressure demonstrates a trend
toward decreased pressures following treatment. However,
the results were not statistically signiﬁcant due to the small
subsetofpatientsinwhompressuresweremeasuredpre-and
posttreatment (n = 7), shown in Table 3.
Following treatment, the intensive care unit (ICU) and
hospital stays were 7.4 days (range 2–27 days) and 21.3 days
(range 6–60 days), respectively. Patients were followed for a
mean of 17.1 months (range = 0.2–32 months). The survival
on an intent to treat basis using the Kaplan Meier survival
curve was 91% (10/11) at 6, 12, and 18 months (95% CI:
80–100%). All 10 surviving patients were functioning wellThrombosis 5
Table 2: Preprocedural and posttreatment change in Miller score and its components.
Preprocedure Posttreatment Mean nominal change in score P-value
Mean Range Mean Range
Obstructive index 13.5 9–16 7.1 1–13 6.4 0.03
Perfusion index 9.8 7–12 7.1 5–14 2.7 0.05
Miller score∗ 23 16–27 13.5 6–27 9.5 0.009
Miller score is the sum of the obstructive and the perfusion indices.
Reference: Miller et al. [21].
without limitation and without further hospitalizations or
oxygen requirement.
4. Discussion
The role of catheter-directed management of acute pul-
monary embolus (PE) associated with hemodynamic insta-
bility and right ventricular dysfunction continues to evolve
and has yet to be determined [4, 25]. However, The
American College of Chest Physicians recommends that
transcatheter thrombectomy not be used for the majority of
patients with acute PE and that it should be reserved for
highly compromised patients with massive PE and either
no time for peripheral ﬁbrinolysis/thrombolysis to work
(acutely critical clinical setting) and/or contraindications to
ﬁbrinolysis/thrombolysis [4, 26]. As a result, transcatheter
management of acute PE is mostly utilized in desperate
clinicalsituationswhicharelikelytobeassociatedwithahigh
likelihood of patient mortality.
However, the speciﬁc clinical application of transcatheter
management of acute PE is still unclear, particularly with
regards to what deﬁnes hemodynamic instability and what
the prognostic criteria are that will help to predict which
patient will beneﬁt from catheter-directed therapy. The
Society of Interventional Radiology Reporting Standards for
Endovascular Treatment of Pulmonary Embolism identiﬁes
risk factors for predicting high mortality rates with acute
PE. These risk factors could be used as relevant inclusion
criteria for employing transcatheter techniques for the
management of acute PE. Risk factors for poor outcome in
patients with massive pulmonary embolus and potentially
relevant inclusion criteria for transcatheter management of
pulmonary embolus. The criteria are the following.
(i) Arterial hypotension < 90mmHg,
(ii) Circulatory collapse requiring cardiopulmonary
resuscitation,
(iii) Shock-causing peripheral hypotension and hypoper-
fusion,
(iv) Right heart strain by echocardiography,
(v) Signiﬁcant pulmonary embolus with contraindica-
tion to anticoagulation,
(vi) Widened arterial-alveolar O2 gradient > 50mmHg,
[4, 27].
However, one can deduce from this that there should be
careful selective criteria, especially given that the unstable
Table 3: Preprocedural and posttreatment pulmonary artery
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immediately and 30% within 30 days [26–31]. In addition,
patients with acute PE and hemodynamic instability have
an associated 3- to 7-fold increase in mortality, with the
majority of these deaths occurring within an hour of
presentation [32]. Another signiﬁcant variable that has
aﬀected the establishment of standard guidelines for use of
catheter-directed therapy for acute PE is the large variety
of mechanical thrombectomy devices and/or techniques uti-
lizedforacutePE;eventhespeciﬁcthrombolyticdrug,doses,
and methods of drug delivery have been highly variable over
the years. In the 1990s, the use of Urokinase (abbokinase,
Abbott Labs, Abbott Park, ILL) predominated within the
United States market, and most operators were familiar with
this drug. In the last decade, tPA has been the most widely
used lytic in the United States market. In addition, there has
been a plethora of mechanical thrombectomy devices and
thrombolysis infusion catheters. This lack of uniformity in
devices and drugs adds to the complexity of reporting on the
experience with transcatheter treatment of acute PE.
The use of the Possis AngioJet for acute PE is a particu-
larly controversial topic due to concerns of its safety in this
vascular bed, particularly in a critically unstable situation [1,
4]. Furthermore, it is diﬃcult to deﬁnitively ascertain, when
reporting bradycardia and asystole within the procedure,
whether these phenomena are from the Possis AngioJet itself,
an eﬀect of the red cell lysis and adenosine release, or from
the underlying condition or a combination.
One of the theoretical advantages of combining tran-
scatheter mechanical thrombectomy and pharmacolysis is
the overall reduction in the lytic dose, the potential for
reducing bleeding complications and the more rapid tempo
of clot clearance, which is suggested in our small series.
Previously published reports have demonstrated a bleeding
rate of approximately 18% for patients with acute, massive
PE treated with thrombolysis [33]. We had only one case6 Thrombosis
(9%) of minor bleeding with no clinical sequelae in our
series.
The major complications reported in the literature
associated with the use of the rheolytic catheter for acute
PE are bradyarrythmias and asystole [1, 4–10]. The cause
of these complication is believed to be secondary to the
hemolysis that occurs with this thrombectomy device and
the subsequent release of adenosine [1, 4–10]. No signiﬁcant
bradyarrythmias were noted in our patients. However,
operators were cognizant of the potential for bradycardia
and activated the AngioJet for short bursts (usually less
than 10 pulses at a time), allowing 20–30 seconds of time
between activations to allow for clearance of compounds,
suchasadenosine,thatmightresultduringdeviceactivation.
The one patient who expired became asystolic shortly into
the procedure, but prior to initiation of any mechanical
thrombectomy device or pharmacolysis. An autopsy was
refused.
The primary aim of catheter-directed therapy (debulking
and/or redistributing the central PE) was demonstrated by
the impact of therapy on the obstructive index (OI) and the
perfusionindex(47%versus28%,resp.).However,thelarger
eﬀect on the OI as compared with the PI is not surprising
given that the mechanical thrombectomy likely caused more
fragmentation in the acute treatment setting than actual
clot removal. Incomplete removal of these small fragmented
pieces of emboli would result in decreased perfusion to
peripheral pulmonary artery branches despite signiﬁcant
improvement in the central, obstructive portion of the clot.
Intheory,catheterinfusionoftPAforatleast12hoursshould
continue to improve the perfusion index.
Most patients in our series were limited to less than 1
week of time in the ICU, with the single outlier being the
patient with acute on chronic thrombus. The patents also
were discharged within 30 days of their diagnosis, again
the only outlier being the patient with acute on chronic
thrombus(whoalsohadIVCocclusion).However,longterm
survivalwasexcellentwith91%(10/11)ofthepatients(10/10
or 100% if the patient who expired prior to initiation of
catheter-directed therapy is excluded from the survival data)
who were alive and well at 18 months of followup. The
mortality rate reported in the literature after mechanical
thrombectomy and pharmaceutical thrombolysis utilizing
the Possis AngioJet approximates 12% [2] which is similar
to our experience. This survival data with percutaneous
therapy is signiﬁcantly better than compared to the overall
population of patients with massive PE which approaches
70% at 30 days from presentation [2, 26–31].
The current study has signiﬁcant limitations owing to its
retrospective nature and its small sample size. These weak-
nesses are the result of careful patient selection for catheter-
directed therapy. Studies of greater substance should involve
multiple centers, preferably in a randomized control trial or
at least in a registry with objective inclusion criteria and a
standardized treatment algorithm.
In addition to these limitations and despite the small
sample size, variations in the catheter-directed treatment
techniques were seen within the study, particularly the use
of the traditional Possis thrombectomy technique (7 cases)
versus the power pulse Possis thrombectomy method (3
cases) due to operator preference rather than objective
criteria. In addition, the Angiojet system provides multiple
catheters, each calibrated to treat varying diameter vessels. In
our series, the Xpeedior catheter, which is intended to treat
up to a 12mm diameter vessel was used since our personal
experience has shown that the other catheters which are
designed to use in larger vessels result in extensive hemolysis
[34]. Other variations contributing to study limitations were
in the pre- and postprocedural diagnostic imaging for PE
load and signs of right heart strain. Furthermore, intra-
and postprocedural pulmonary artery pressures and oxygen
saturations were not obtained consistently to allow for acute
quantitative analysis of the hemodynamic eﬀects of the
therapy.
In conclusion, patients with acute PE who present with
evidence for right ventricular strain or an acute PEA event
can be treated with percutaneous mechanical thrombectomy
with the Possis Angiojet with or without adjunctive use of
indwelling catheter-directed pharmacolysis relatively safely
with very good early and mid-range survival outcomes.
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